|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
EP0832073B1
(en)
*
|
1995-06-07 |
2002-01-16 |
Sugen, Inc. |
Quinazolines and pharmaceutical compositions
|
|
US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
|
US6147106A
(en)
*
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
|
NZ510991A
(en)
|
1997-03-05 |
2002-11-26 |
Sugen Inc |
Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
|
US6051593A
(en)
*
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
|
US6153634A
(en)
*
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
|
EP1157019B1
(en)
*
|
1998-12-17 |
2003-03-19 |
F. Hoffmann-La Roche Ag |
4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
|
|
BR9916324A
(pt)
*
|
1998-12-17 |
2001-10-02 |
Hoffmann La Roche |
4,5-pirazinoxindóis como inibidores de proteìna quinase
|
|
JP2002532493A
(ja)
|
1998-12-17 |
2002-10-02 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｊｎｋプロテインキナーゼ阻害剤としての４−アリールオキシインドール
|
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
|
JP2002540096A
(ja)
*
|
1999-03-24 |
2002-11-26 |
スージェン・インコーポレーテッド |
キナーゼ阻害剤としてのインドリノン化合物
|
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
|
JP2000281588A
(ja)
*
|
1999-03-30 |
2000-10-10 |
Sankyo Co Ltd |
ガンの予防又は治療薬及びそのスクリーニング方法
|
|
EP1173254A2
(en)
*
|
1999-04-27 |
2002-01-23 |
Smithkline Beecham Plc |
Novel treatment of neurotraumatic conditions with a raf inhibitor
|
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
|
ES2267605T3
(es)
|
1999-12-22 |
2007-03-16 |
Sugen, Inc. |
Uso de compuestos de indolinona para la fabricacion de productos farmaceuticos destinados a modular la funcion de la c-kit-tirosina-proteina-quinasa.
|
|
US6339100B1
(en)
*
|
1999-12-29 |
2002-01-15 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting mastocytosis
|
|
AU2001236720A1
(en)
*
|
2000-02-05 |
2001-08-14 |
Bemis, Guy |
Compositions useful as inhibitors of erk
|
|
US6573293B2
(en)
|
2000-02-15 |
2003-06-03 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
|
MY128449A
(en)
|
2000-05-24 |
2007-02-28 |
Sugen Inc |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
|
US6706709B2
(en)
|
2000-06-02 |
2004-03-16 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
|
CA2417500C
(en)
*
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Erbb-2 selective small molecule kinase inhibitors
|
|
ATE281455T1
(de)
|
2000-09-01 |
2004-11-15 |
Glaxo Group Ltd |
Oxindolderivate
|
|
DE10054019A1
(de)
*
|
2000-11-01 |
2002-05-23 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
|
US6638965B2
(en)
|
2000-11-01 |
2003-10-28 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
|
|
EP1488809A1
(en)
|
2001-01-16 |
2004-12-22 |
Glaxo Group Limited |
Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
|
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
|
JP2004529110A
(ja)
|
2001-03-06 |
2004-09-24 |
アストラゼネカ アクチボラグ |
脈管損傷活性を有するインドール誘導体
|
|
US6599902B2
(en)
|
2001-05-30 |
2003-07-29 |
Sugen, Inc. |
5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
|
DE10134196B4
(de)
*
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
|
JP2005508337A
(ja)
*
|
2001-09-27 |
2005-03-31 |
スミスクライン ビーチャム コーポレーション |
化合物
|
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
US20030119839A1
(en)
*
|
2001-12-13 |
2003-06-26 |
Nan-Horng Lin |
Protein kinase inhibitors
|
|
GB0206861D0
(en)
*
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Medicaments
|
|
WO2003084951A1
(en)
*
|
2002-04-03 |
2003-10-16 |
Allergan, Inc. |
(3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
|
|
US6541504B1
(en)
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
|
EP1492568A1
(en)
*
|
2002-04-08 |
2005-01-05 |
SmithKline Beecham Corporation |
Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor
|
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
|
US7585866B2
(en)
*
|
2002-07-31 |
2009-09-08 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
|
BR0313743A
(pt)
*
|
2002-08-23 |
2005-07-05 |
Chiron Corp |
Benzimidazol quinolinonas e usos destas
|
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
|
US8673924B2
(en)
|
2002-09-04 |
2014-03-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
|
PT1537116E
(pt)
|
2002-09-04 |
2010-09-03 |
Schering Corp |
Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas
|
|
EP1551824B1
(en)
*
|
2002-10-09 |
2007-12-12 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
|
SG148864A1
(en)
*
|
2002-11-13 |
2009-01-29 |
Chiron Corp |
Methods of treating cancer and related methods
|
|
CA2506546A1
(en)
*
|
2002-11-15 |
2004-06-17 |
Exelixis, Inc. |
Kinase modulators
|
|
US20050019366A1
(en)
*
|
2002-12-31 |
2005-01-27 |
Zeldis Jerome B. |
Drug-coated stents and methods of use therefor
|
|
WO2004064733A2
(en)
*
|
2003-01-15 |
2004-08-05 |
Board Of Regents, University Of Texas System |
The use of c-raf inhibitors for the treatment of neurodegenerative diseases
|
|
EP1631291B1
(en)
*
|
2003-05-27 |
2009-08-12 |
Robert P. Hägerkvist |
Use of tyrosine kinase inhibitors to treat diabetes
|
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
|
CA2542653A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Chiron Corporation |
Substituted benzazoles and use thereof as inhibitors of raf kinase
|
|
KR101167573B1
(ko)
*
|
2003-11-07 |
2012-07-30 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
|
|
WO2005068424A1
(en)
*
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Indolinone derivatives as receptor tyrosine kinase ihibitors
|
|
EP1719771A1
(en)
*
|
2004-02-19 |
2006-11-08 |
Takeda Pharmaceutical Company Limited |
Pyrazoloquinolone derivative and use thereof
|
|
WO2005082340A2
(en)
*
|
2004-02-20 |
2005-09-09 |
Chiron Corporation |
Modulation of inflammatory and metastatic processes
|
|
DE102004012070A1
(de)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
|
|
NZ561215A
(en)
|
2005-02-22 |
2010-12-24 |
Univ Michigan |
Small molecule inhibitors of MDM2 and uses thereof
|
|
US8299081B2
(en)
*
|
2005-05-13 |
2012-10-30 |
Novartis Ag |
Methods for treating drug resistant cancer
|
|
EP1904480A2
(en)
|
2005-05-23 |
2008-04-02 |
Novartis Pharma AG |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
|
|
PE20070427A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
|
|
JP2009517481A
(ja)
*
|
2005-11-29 |
2009-04-30 |
ノバルティス アクチエンゲゼルシャフト |
キノリノンの製剤
|
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
|
ES2353437T3
(es)
|
2006-02-16 |
2011-03-02 |
Schering Corporation |
Derivados de pirrolidina como inhibidores de erk.
|
|
DK2046292T3
(da)
*
|
2006-07-21 |
2010-06-07 |
Novartis Ag |
Formuleringer for benzimidazolylpyridylethere
|
|
RU2009114745A
(ru)
*
|
2006-09-19 |
2010-10-27 |
Новартис АГ (CH) |
Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования
|
|
US8034815B2
(en)
|
2007-01-11 |
2011-10-11 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
|
US20110129550A1
(en)
|
2007-02-16 |
2011-06-02 |
Connie Erickson-Miller |
Cancer treatment method
|
|
US20110160130A1
(en)
*
|
2007-02-16 |
2011-06-30 |
Connie Erickson-Miller |
Cancer treatment method
|
|
UY30915A1
(es)
|
2007-02-16 |
2008-09-02 |
Smithkline Beecham Corp |
Método de tratamiento de canceres
|
|
US20100143440A1
(en)
*
|
2007-04-30 |
2010-06-10 |
The Uab Research Foundation |
Ul97 inhibitors for treatment of proliferative disorders
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
AR066845A1
(es)
|
2007-06-05 |
2009-09-16 |
Takeda Pharmaceutical |
Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
|
|
EP2181987B9
(en)
|
2007-08-23 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
|
|
EP2184285B1
(en)
|
2007-08-29 |
2015-11-04 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
|
US8299106B2
(en)
*
|
2007-09-06 |
2012-10-30 |
Boston Biomedical, Inc. |
Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
|
|
CN101888841B
(zh)
*
|
2007-10-09 |
2012-09-26 |
宾夕法尼亚大学理事会 |
血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞
|
|
AU2008340991B2
(en)
|
2007-12-21 |
2012-02-23 |
University Health Network |
Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
|
|
CA2710039C
(en)
|
2007-12-26 |
2018-07-03 |
Critical Outcome Technologies, Inc. |
Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
|
|
SG188179A1
(en)
|
2008-02-21 |
2013-03-28 |
Merck Sharp & Dohme |
Compounds that are erk inhibitors
|
|
EP2318406B1
(en)
|
2008-07-17 |
2016-01-27 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
EP2362775B1
(en)
|
2008-11-20 |
2015-08-05 |
GlaxoSmithKline LLC |
Chemical compounds
|
|
WO2010064611A1
(ja)
|
2008-12-01 |
2010-06-10 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
|
NZ593110A
(en)
|
2008-12-09 |
2013-06-28 |
Gilead Sciences Inc |
pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
|
|
MY161598A
(en)
|
2009-01-30 |
2017-04-28 |
Glaxosmithkline Llc |
Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
|
|
WO2010100127A1
(en)
|
2009-03-04 |
2010-09-10 |
Novartis Ag |
Disubstituted imidazole derivatives as modulators of raf kinase
|
|
WO2010115279A1
(en)
|
2009-04-06 |
2010-10-14 |
University Health Network |
Kinase inhibitors and method of treating cancer with same
|
|
US8410095B2
(en)
|
2009-05-20 |
2013-04-02 |
Glaxosmithkline Llc |
Thiazolopyrimidinone derivatives as PI3 kinase inhibitors
|
|
HRP20190016T1
(hr)
|
2009-08-17 |
2019-03-08 |
Intellikine, Llc |
Heterociklički spojevi i njihova upotreba
|
|
SG178439A1
(en)
|
2009-08-21 |
2012-04-27 |
Smithkline Beecham Cork Ltd |
Method of treating cancer
|
|
IN2012DN02596A
(enExample)
|
2009-08-26 |
2015-08-28 |
Cylene Pharmaceuticals Inc |
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
|
CA2772253C
(en)
|
2009-09-14 |
2018-02-27 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
HUE067723T2
(hu)
|
2009-10-16 |
2024-11-28 |
Novartis Ag |
MEK-inhibitort és B-Raf-inhibitort tartalmazó kombináció
|
|
CA2777824C
(en)
|
2009-10-22 |
2016-11-29 |
Gilead Sciences, Inc. |
Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
|
|
WO2011057204A2
(en)
*
|
2009-11-06 |
2011-05-12 |
The Johns Hopkins University |
Lrrk2-mediated neuronal toxicity
|
|
EP2531498B1
(en)
|
2010-02-05 |
2016-07-13 |
Novartis AG |
Compounds and compositions as protein kinase inhibitors
|
|
US8598156B2
(en)
|
2010-03-25 |
2013-12-03 |
Glaxosmithkline Llc |
Chemical compounds
|
|
CA2999435A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
|
TWI516262B
(zh)
|
2010-04-06 |
2016-01-11 |
健康網路大學 |
激酶抑制劑及以其治療癌症的方法
|
|
CA2803055A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Heteroaryl compounds and compositions as protein kinase inhibitors
|
|
JP6185839B2
(ja)
|
2010-09-14 |
2017-08-23 |
ノバルティス アーゲー |
Ｂｒａｆ阻害薬とｖｅｇｆ阻害薬との組み合わせ
|
|
PE20140192A1
(es)
|
2010-10-06 |
2014-02-24 |
Glaxosmithkline Llc |
Derivados de bencimidazol como inhibidores de cinasa pi3
|
|
GB201112607D0
(en)
|
2011-07-22 |
2011-09-07 |
Glaxo Group Ltd |
Novel compounds
|
|
TWI505828B
(zh)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產（第二）有限公司 |
新穎醫藥組成物
|
|
MX356704B
(es)
|
2011-01-11 |
2018-06-11 |
Novartis Ag |
Combinación.
|
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン， エルエルシー |
複素環化合物およびその使用
|
|
WO2013070996A1
(en)
|
2011-11-11 |
2013-05-16 |
Novartis Ag |
Method of treating a proliferative disease
|
|
EP2782557B1
(en)
|
2011-11-23 |
2018-09-12 |
Array Biopharma, Inc. |
Pharmaceutical formulations
|
|
AU2013214254B2
(en)
|
2012-01-31 |
2016-04-21 |
Novartis Ag |
Method of treating cancer
|
|
WO2013143597A1
(en)
|
2012-03-29 |
2013-10-03 |
Glaxo Group Limited |
Demethylase enzymes inhibitors
|
|
CN104955824B
(zh)
|
2012-11-20 |
2017-09-22 |
豪夫迈·罗氏有限公司 |
作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物
|
|
IL300664A
(en)
|
2012-11-30 |
2023-04-01 |
Novartis Ag |
Innovative pharmaceutical composition
|
|
AU2014206138A1
(en)
|
2013-01-09 |
2015-07-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination
|
|
ES2651331T3
(es)
|
2013-01-10 |
2018-01-25 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Inhibidores de la sintasa de ácidos grasos
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
AU2014243869A1
(en)
*
|
2013-03-13 |
2015-09-24 |
Boston Biomedical, Inc. |
3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
HK1219421A1
(zh)
|
2013-03-15 |
2017-04-07 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
|
KR20160013049A
(ko)
|
2013-06-03 |
2016-02-03 |
노파르티스 아게 |
항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
|
|
WO2014210354A1
(en)
|
2013-06-28 |
2014-12-31 |
Genentech, Inc. |
Azaindazole compounds as inhibitors of t790m containing egfr mutants
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
EP3718544A1
(en)
|
2013-10-01 |
2020-10-07 |
Novartis AG |
Combination
|
|
US20160235714A1
(en)
|
2013-10-01 |
2016-08-18 |
Novartis Ag |
Enzalutamide in combination with afuresertib for the treatment of cancer
|
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
|
MX357763B
(es)
|
2013-10-18 |
2018-07-23 |
Univ Health Network |
Tratamiento para cancer pancreatico.
|
|
WO2015087279A1
(en)
|
2013-12-12 |
2015-06-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
|
|
US20160361309A1
(en)
|
2014-02-26 |
2016-12-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
|
CN106456642A
(zh)
|
2014-03-12 |
2017-02-22 |
诺华股份有限公司 |
含btk抑制剂与akt抑制剂的组合
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
|
EA201790024A1
(ru)
|
2014-07-11 |
2017-07-31 |
Джилид Сайэнс, Инк. |
Модуляторы toll-подобных рецепторов для лечения вич
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
US9738646B2
(en)
|
2014-09-16 |
2017-08-22 |
Gilead Sciences, Inc. |
Solid forms of a toll-like receptor modulator
|
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
|
US20180222989A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
WO2017021910A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
AU2016303387B2
(en)
|
2015-08-06 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
TLR4 agonists and compositions thereof and their use in the treatment of cancer
|
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
EP4015537A1
(en)
|
2015-12-01 |
2022-06-22 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
RU2020113165A
(ru)
|
2015-12-03 |
2020-06-09 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Циклические пуриновые динуклеотиды в качестве модуляторов sting
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
NZ746112A
(en)
|
2016-03-18 |
2023-01-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
JP2019510802A
(ja)
|
2016-04-07 |
2019-04-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
タンパク質調節物質として有用な複素環アミド
|
|
CN113549110B
(zh)
|
2016-04-07 |
2024-08-16 |
葛兰素史密斯克莱知识产权发展有限公司 |
用作蛋白质调节剂的杂环酰胺
|
|
JP2019521166A
(ja)
|
2016-07-20 |
2019-07-25 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｐｅｒｋ阻害剤としてのイソキノリン誘導体
|
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
CA3037456A1
(en)
|
2016-09-19 |
2018-03-22 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
MX2019007649A
(es)
|
2016-12-23 |
2019-09-10 |
Arvinas Operations Inc |
Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
|
|
WO2018119441A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
|
US20190375847A1
(en)
|
2017-02-15 |
2019-12-12 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
IL270224B1
(en)
|
2017-05-02 |
2024-04-01 |
Novartis Ag |
Combination therapy employing trametinib and a defined raf inhibitor
|
|
KR20200024890A
(ko)
|
2017-07-05 |
2020-03-09 |
노파르티스 아게 |
신규한 약학적 조성물
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
JP2020536106A
(ja)
|
2017-10-05 |
2020-12-10 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
|
|
BR112020006780A2
(pt)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
moduladores do estimulador de genes do interferon (sting)
|
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
EP3801069A4
(en)
|
2018-06-01 |
2022-03-16 |
Cornell University |
MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
|
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
|
MX2021001033A
(es)
*
|
2018-08-07 |
2021-07-07 |
Metagone Biotech Inc |
Sales de amonio de 3-(3,5-dibromo-4-hidroxibencilideno)-5-indo-1,3 -dihidroindol-2-ona y sus usos.
|
|
US12390460B2
(en)
*
|
2018-09-18 |
2025-08-19 |
1Globe Biomedical Co., Ltd. |
Treatment for obesity
|
|
WO2020110056A1
(en)
|
2018-11-30 |
2020-06-04 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in hiv therapy
|
|
CA3128064A1
(en)
|
2019-02-01 |
2020-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
|
|
EP4563150A3
(en)
|
2019-05-13 |
2025-07-23 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
|
|
JP2022533390A
(ja)
|
2019-05-16 |
2022-07-22 |
スティングセラ インコーポレイテッド |
オキソアクリジニル酢酸誘導体および使用方法
|
|
EP3969452A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
|
BR112021025476A2
(pt)
|
2019-06-26 |
2022-10-11 |
Glaxosmithkline Ip Dev Ltd |
Proteínas de ligação à il1rap
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021046293A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
|
|
CN114981265B
(zh)
|
2019-12-18 |
2025-01-03 |
Ctxt私人有限公司 |
化合物
|
|
EP4096718A1
(en)
|
2020-01-28 |
2022-12-07 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
EP4204418A1
(en)
|
2020-08-28 |
2023-07-05 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
CN114573453B
(zh)
*
|
2020-12-02 |
2024-12-03 |
荆楚理工学院 |
一种选择性的羧酸酯裂解方法
|
|
KR20240041917A
(ko)
|
2021-07-27 |
2024-04-01 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
|
KR102566028B1
(ko)
*
|
2021-08-10 |
2023-08-10 |
계명대학교 산학협력단 |
신규한 다중 단백질 키나아제 억제제
|
|
CN114671887A
(zh)
*
|
2021-10-29 |
2022-06-28 |
四川大学华西医院 |
一种二氢吲哚酮类化合物的制备及其抗肿瘤应用
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
TW202432544A
(zh)
|
2022-09-07 |
2024-08-16 |
美商亞文納營運公司 |
快速加速纖維肉瘤降解化合物及相關使用方法
|